The Institute for Clinical and Economic Review’s traditional value assessment methodologies for complex conditions such as Alzheimer’s disease fail to address the full burden on patients, caregivers and society, according to a report released Wednesday by the Alliance for Aging Research.
The report examines traditional assessment challenges from several angles. There’s a look at using cost effectiveness to judge therapeutic value from a payer’s perspective. There’s also an analysis of quality adjusted life years, in which the authors raise serious concerns because the approach does not recognize value driven by public health improvement, transformation or societal value.
Turning to solutions, the report authors suggest an alternative, equitable value assessment framework for use in Alzheimer’s that accounts for the ecosystem surrounding those with Alzheimer’s. This framework includes the effect that treatments may have on improving social inequities, such as racial disparities. Those suggestions are particularly well timed since ICER just released its proposed value assessment approach for Alzheimer’s and currently is inviting public comment.
The study is available here.
